BRPI0719182A2 - Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b - Google Patents

Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b

Info

Publication number
BRPI0719182A2
BRPI0719182A2 BRPI0719182-0A2A BRPI0719182A BRPI0719182A2 BR PI0719182 A2 BRPI0719182 A2 BR PI0719182A2 BR PI0719182 A BRPI0719182 A BR PI0719182A BR PI0719182 A2 BRPI0719182 A2 BR PI0719182A2
Authority
BR
Brazil
Prior art keywords
dislipidemic
omega
levels
agent
fatty acids
Prior art date
Application number
BRPI0719182-0A2A
Other languages
English (en)
Inventor
Roelof M L Rongen
Robert A Shalwitz
Douglas Kling
Ralph T Doyle Jr
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of BRPI0719182A2 publication Critical patent/BRPI0719182A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0719182-0A2A 2006-10-10 2007-10-10 Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b BRPI0719182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85028006P 2006-10-10 2006-10-10
PCT/US2007/021631 WO2008045465A1 (en) 2006-10-10 2007-10-10 Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels

Publications (1)

Publication Number Publication Date
BRPI0719182A2 true BRPI0719182A2 (pt) 2014-10-21

Family

ID=39283166

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719182-0A2A BRPI0719182A2 (pt) 2006-10-10 2007-10-10 Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b

Country Status (10)

Country Link
EP (1) EP2089014A4 (pt)
JP (1) JP2010505956A (pt)
KR (1) KR20090080070A (pt)
CN (2) CN101553221A (pt)
AU (1) AU2007307007A1 (pt)
BR (1) BRPI0719182A2 (pt)
CA (1) CA2672919A1 (pt)
EA (2) EA018734B1 (pt)
MX (1) MX2009003921A (pt)
WO (1) WO2008045465A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
JP2010506920A (ja) * 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR101383006B1 (ko) 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh) * 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
JP6227535B2 (ja) * 2012-08-30 2017-11-08 株式会社三和化学研究所 脂質異常症の予防又は治療薬
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
MX369471B (es) * 2014-02-05 2019-11-08 Dezima Pharma B V Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares.
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014359A1 (en) * 2001-03-16 2004-02-19 Thomas Jefferson University Regulation of apob in treatment and drug screening for cardiovascular and metabolic disorders or syndromes
CA2589654C (en) * 2004-12-06 2016-02-16 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
KR20080037674A (ko) * 2005-07-18 2008-04-30 릴라이언트 파마슈티컬스 인코퍼레이티드 아제티디논계 콜레스테롤 흡수 억제제 및 오메가-3 지방산및 이들의 조합물로의 치료

Also Published As

Publication number Publication date
CA2672919A1 (en) 2008-04-17
EA200970360A1 (ru) 2009-10-30
EA018734B1 (ru) 2013-10-30
JP2010505956A (ja) 2010-02-25
AU2007307007A1 (en) 2008-04-17
CN101553221A (zh) 2009-10-07
KR20090080070A (ko) 2009-07-23
CN101553220A (zh) 2009-10-07
EP2089014A4 (en) 2009-12-09
MX2009003921A (es) 2009-08-31
WO2008045465A1 (en) 2008-04-17
EA200970359A1 (ru) 2009-10-30
EP2089014A1 (en) 2009-08-19

Similar Documents

Publication Publication Date Title
BRPI0719182A2 (pt) Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b
ZA201003030B (en) Medium-chain length fatty acids and glycerides as nephroprotection agents
EP1872724A4 (en) ULTRASONOGRAPH AND METHOD FOR CREATING AN ULTRASONOGRAM
PT1773312E (pt) Composição contendo estatinas e ácidos graxos ómega-3
BRPI0921467A2 (pt) Enzimas e métodos para produzir ácidos graxos ômega-3
DK1385498T3 (da) Fedtsyrer som overlevelses- og aktiveringsfaktorer for neutrofiler
IL210233A0 (en) Omega 3 fatty acid formulations
EP1830830A4 (en) OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC MEANS FOR LIPID THERAPY
CL2007003761A1 (es) Composicion liquida de limpieza personal que comprende isetionatos de acilo graso, cosurfactante, alcanolamida y/o alquilaminaoxido, acidos grasos de cadena recta o mezcla con alcoholes grasos de cadena recta y/o aceites de hidrocarburo alifatico, la
BRPI0717027A2 (pt) Hidrocarbonetos e ácidos graxos de cadeias de comprimento médio de algas
BRPI0911606A2 (pt) Polipeptídeo e métodos para produzir triacilgliceróis compreendendo ácidos graxos modificados
EP1940423A4 (en) METHODS AND COMPOSITIONS OF TISSUE GENIUS
BRPI0719594A2 (pt) Partícula de liberação contendo agente de benefício
BRPI0819026A2 (pt) "método para produzir um gel aquoso de adapaleno e gel aquoso de adapaleno"
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
BRPI0816640A2 (pt) "método para produzir produtos de proteína estável ácida e produtos assim produzidos"
BR0304676B1 (pt) inversor de empuxo para turborreator
PT1418225E (pt) Agente desinfectante e desodorizante para sanitas
BRPI0716765A2 (pt) mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço
CL2011000290A1 (es) Método para extraer ácidos grasos poliinsaturados de cadena larga; composición de aceite y su uso en tratamiento cosméticos o terapéuticos.
CL2004001004A1 (es) Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
PL1948358T3 (pl) Zastosowanie kompozycji katalizatora i sposób oksychlorowania
BR0304675B1 (pt) inversor de empuxo para turborreator
BRPI0717202A2 (pt) emulsço edÍvel e usos
BRPI0717710A2 (pt) Método para preparar óleo de margarina e óleo de margarina

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 60/850,280 DE 10/10/2006 REIVINDICADA NO PCT/US2007/021631, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. OBSERVA-SE QUE A PRIORIDADE US 60/850,280 DE 10/10/2006 POSSUI COMO TITULAR "ROELOF M. L. RONGEN" E "ROBERT A. SHALWITZ". ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("RELIANT PHARMACEUTICALS, INC.") SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]